The world’s first COVID-19 vaccine has been developed with the help of plants to fight the coronavirus.
The vaccine, co-administered by Medicago, a subsidiary of Mitsubishi Chemical Holdings Corporation, GlaxoSmithKline, and Philip Morris International
The vaccine will be available for ages 18 to 64, according to a statement from the companies.
He said the vaccine is easier to deliver and store than an mRNA vaccine because it does not need to be kept at very low temperatures.
The vaccine is based on proteins found in plants that make the immune system look like the coronavirus so that it can be prepared to fight it.
A special pandemic adjuvant of GlaxoSmithKline has also been used in vaccines to boost the immune system response.
An agreement has been reached to supply 76 million doses of the vaccine to Canada, while Medicago is in talks with other countries.
The statement added that the vaccine is up to 71% effective in protecting against various types of coronavirus.
These are the results of clinical trials up to December 2021.
Its efficacy was 75% against corona type delta and about 89% against gamma type.
At the moment, since the Omicron type was not widespread, the company plans to work on more trials.